TOKYO -- Fujifilm Holdings' flu-fighting drug Avigan failed to prove sustained clinical recovery from COVID-19 in a test conducted by a Canadian partner in the U.S., Mexico and Brazil, significantly hampering its chances of implication in the American market.
Appili Therapeutics, the Halifax-based partner, said the Phase 3 clinical trial evaluating oral antiviral Avigan for the treatment of mild to moderate COVID-19 "did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery." Additional analyses of the trial data are ongoing, the company said in a news release Friday.
